Elanco Animal Health Inc (5EA.DE) Q4 2025 Earnings Report

Elanco Animal Health reported Q4 2025 revenue of $1.144 billion, marking a YoY rise of about 12.2% and a modest QoQ increase of 0.6%. The quarter benefited from a robust gross margin of 74.6% (gross profit of $0.853 billion), reflecting the strength of its core product portfolio. However, the bottom line deteriorated sharply, with net income of -$0.276 billion and a negative net margin of -24.1%, driven primarily by a substantial non-operating charge of -$0.821 billion in total other income/expenses, which dwarfed operating gains. Operating income remained healthy at $0.562 billion (operating margin ~49.1%), underscoring strong core profitability on an operating basis, but the company faces a difficult path to net profitability without normalization of non-operating items and favorable tax treatment going forward.

Over the four-quarter window, Elanco demonstrated revenue resilience with sequential fluctuations: Q1 2025 revenue $1.193B, Q2 $1.241B, Q3 $1.137B, and Q4 $1.144B. The margin and earnings trajectory highlight a bifurcated performance where operating discipline and product mix delivered solid gross and operating margins, but non-operating line items and tax dynamics introduced meaningful volatility to the reported bottom line. Management commentary (where available) centers on sustaining core margins, advancing pipeline and product launches, and managing cost structures in a high-inflation environment. Investors should monitor normalization of other income/expenses, currency translation effects for a USD-denominated report on a German exchange, and ongoing capital allocation initiatives as drivers of sustainable earnings.